首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
Once-daily Pill Could Simplify HIV Treatment Bristol-Myers Squibb and Gilead Sciences have combined many HIV drugs into a si
Once-daily Pill Could Simplify HIV Treatment Bristol-Myers Squibb and Gilead Sciences have combined many HIV drugs into a si
admin
2011-01-05
77
问题
Once-daily Pill Could Simplify HIV Treatment
Bristol-Myers Squibb and Gilead Sciences have combined many HIV drugs into a single pill. Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and HIV/ AIDS, for example, are all treated with (51) of drugs. But that can mean a lot of pills to take. It would be (52) if drug companies combined all the medicines into a single pill, taken just once a day.
Now, two companies say they have done that for people just (53) treatment for HIV, the virus, that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences. They have (54) a single pill that combines three drugs currently on the market. Bristol-Myes Squibb sells one of them (55) the name of Sustiva. Gilead combined the (56) , Emtriva and Viread, into a single pill in two thousand four.
Combining drugs involves more than (57) issues. It also involves issues of competition (58) the drugs are made by different companies. The new once-daily pill is the result of (59) is described as the first joint venture agreement of its kind in the treatment of HIV.
In January the New England Journal of Medicine published a study of the new pill. Researchers compared its (60) to that of the widely used combination of Sustiva and Combivir. Combivir (61) two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed HIV levels in more patients and with (62) side effects. Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research.
Glaxo Smith Kine reacted (63) the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.
The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries. They plan in the next few months to ask the United States Food and Drug Administration to (64) the new pill.
There are limits to who could take it because of the different drugs it contains. For example, (65) women are told not to take Sustiva because of the risk of birth disorders. Experts say more that forty million people around the world are living with HIV.
选项
A、for
B、with
C、to
D、into
答案
C
解析
react…to(“对……作出反应”)是固定用法,其他选项均不对。
转载请注明原文地址:https://kaotiyun.com/show/Demd777K
本试题收录于:
职称英语卫生类A级题库职称英语分类
0
职称英语卫生类A级
职称英语
相关试题推荐
Amy:Ican’tdecidewhatsubjecttostudyatuniversity.Helen:16______Amy:Ialwaysdowellinchemistryexams.Helen:17__
Theworkersfinallycalledoffthestrike.
HowtoJumpQueueFuryIfyoufindyourselfwaitinginalongqueueatanairportorbusterminusthisholiday,willyoutry
HowOneSimpleMovementCanLetSliptheSecretsoftheMindBodylanguageisthequiet,secretandmostpowerfullanguageofal
Inthepast,doctorscouldn’tdoanythingaboutstomachulcers.Doctorshavediscoveredacauseofulcersaftermanyyearsofe
Ittookmeexactlyaweektocompletethework.
HowmanybabiesarebornwithlowbirthweightinthedevelopedcountrieseveryyearaccordingtoWHO?Howmanypercentofbabi
Awillisadocumentwrittentoensurethatthewishesofthedeceasedarerealized.
MyExperienceaboutEnglishOnesummernight,onmywayhomefromworkIdecidedtoseeamovie.Iknewthetheatrewouldbeair
WhatIsInsulin-dependentDiabetes?Whenyoueat,yourbodytakesthesugarfromfoodandturnsitintofuel.【B1】______Your
随机试题
榭是小巧玲珑、开敞精致的建筑物。()
某商场在春节期间组织“家家乐”家用电器促销活动,有关部门发现其销售的部分电器中有侵犯他人专利权或商标权的产品。该商场能证明其产品的合法来源。关于该商场的行为,下列选项正确的是()
A.夜间阵发性呼吸困难,不能平卧,咯泡沫痰B.夜间阵发性呼吸困难,能平卧,咳白黏痰C.下垂性双下肢对称性水肿D.晨起面部浮肿E.颈静脉怒张,肝颈回流征阳性心源性水肿
门脉高压症分流术后护理不正确的是
关于分界线说法正确的有()。
直接根据记账凭证逐笔登记总分类账的账务处理程序是()。
在公司内部控制的主要内容中,不属于投资管理业务控制的是()。
下列做法正确的是:
BSP指______。
Standardsforcommercialeggproductionvarygreatlyaroundthecountry.Inmoststates,theegg-layinghensare【S1】______togeth
最新回复
(
0
)